PRELUDE THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
PRELUDE THERAPEUTICS INC. - More news...
PRELUDE THERAPEUTICS INC. - More news...
- Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
- Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
- Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
- Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
- Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
- Prelude Therapeutics Reports Full Year 2021 Financial Results
- Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
- Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
- Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
- Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
- Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
- Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
- Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
- Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
- Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
- Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
- Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
- Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
- Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
- Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
- Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
- Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences
- Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Prelude Therapeutics Announces Pricing of Upsized Public Offering
- Prelude Therapeutics Announces Launch of Proposed Public Offering
- Prelude Therapeutics Announces Third Quarter 2020 Financial Results
